Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Long-term Extension, Multicentre, Multi-national Study to Evaluate the Safety and Tolerability of Oral BAY63-2521 (1mg, 1.5 mg, 2.0 mg, 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)

Next Previous
X
Search
Trial Profile

Long-term Extension, Multicentre, Multi-national Study to Evaluate the Safety and Tolerability of Oral BAY63-2521 (1mg, 1.5 mg, 2.0 mg, 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Riociguat (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions; Registrational
  • Acronyms PATENT-2
  • Sponsors Bayer; Bayer HealthCare

    • Most Recent Events

    • 13 Nov 2023 Results of post-hoc analysis assessing COMPERA 2.0 to the PATENT 1& PATENT 2 studies of riociguat in patients with pulmonary arterial hypertension, presented at the American Heart Association Scientific Sessions 2023.
    • 28 Oct 2021 Results(n=396) from PATENT-1 and PATENT-2, investigating the effect of riociguat on REVEAL Lite 2 score, published in the Journal of Heart and Lung Transplantation
    • 01 Jun 2021 Results of post hoc exploratory analysis; evaluating REVEAL risk score (RRS)2.0 in the PATENT study and assessing the relationship between RRS 2.0 and survival and clinical worsening-free survival from PATENT-1 and 2; published in the International Journal of Cardiology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top